ABBV vs META: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Meta Platforms, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-15.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Meta Platforms, Inc. · Communication Services
$665.60
+21.4% upside to fair value
Med Conviction
Grade B+
High Quality
QuantHub Verdict
META has more upside to fair value
(+21.4%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
META |
| Current Price |
$261.70 |
$665.60 |
| Fair Value Estimate |
$259.04 |
$808.00 |
| Upside to Fair Value |
-1.0%
|
+21.4%
|
| Market Cap |
$462.4B |
$1,695.6B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
16.7x
|
| Price / Sales |
7.2x
|
7.4x
|
| Price / FCF |
23.6x
|
41.3x
|
| Revenue Growth YoY |
+10.2%
|
+28.0%
|
| Gross Margin |
71.5%
|
81.7%
|
| Operating Margin |
29.3%
|
38.1%
|
| Return on Equity |
-136.5%
|
29.7%
|
| Dividend Yield |
2.61% |
0.32% |
| FCF Yield |
4.25%
|
2.42%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Meta Platforms operates the Facebook, Instagram, WhatsApp, Messenger and Threads ecosystem, monetizing its unmatched global audience primarily through digital advertising. Business quality is high, supported by 3.60 billion Family daily active people, AI-enhanced ad ranking, 81.7% TTM gross margin, 38.1% TTM operating margin, 29.8% TTM net margin and 29.7% ROE. Revenue grew 28.0% year over year i…
Accumulation Zones
| Metric |
ABBV |
META |
| Zone Low |
$194.28 |
$606.00 |
| Zone High |
$220.18 |
$686.80 |
| In Buy Zone? |
No
|
Yes
|